VMAT2 Inhibitor Treatment for TD Is Complex and Patient-Specific

figure img { width:100% !important; } figcaption { padding: 5px; background: transparent; word-wrap: normal; text-align: center; font-size:10px; line-height: 12px; }Credit: toa555 –stock.adobe.comBy Marcus A. BanksPharmacists can play an active role in guiding patients on the use of vesicular monoamine transporter 2 (VMAT2) inhibitors for tardive dyskinesia (TD), according to an expert who discussed key TD counseling points at the American Association of Psychiatric Pharmacists 2025 Annual